Download A New Scientific Breakthrough Addressing Multiple Cancers

A New Scientific Breakthrough
Addressing Multiple Cancers
Oren Gilad
President and CEO
[email protected]
215-589-6356
Bernard Rudnick
Chief Financial Officer
[email protected]
302-981-9001
Cancer drug sales exceed $100 billion in the US
 $300 billion market - $100 billion is chemotherapy
 Addressable market at $40 billion
 Aggressive cancers have poor or absent solutions
 Only 2 of 100 largest pharmas have Phase 1 ATR data
 Orally available - drives higher prescribing activity
 Lead molecule, ATRN-119, is a Best-In-Class ATR inhibitor
 Water soluble, orally bioavailable, highly potent
 Addressing a wide spectrum of cancers; reimbursable
Non-Confidential
2
ATRN-119 Single Agent and Combinational Therapy:
Indication of Efficacy Without Adverse Side Effects
Human BRCA2-mutant Ovarian Cancer PDX
900
Tumor volume (mm3)
800
Control
700
600
500
ATRN-119
Olaparib
400
300
200
ATRN-119 +
Olaparib
100
0
0
1
2
3
4
Time (weeks)
5
6
Simply put, Atrin’s non-optimized molecule in combination with the usual drug
took tumor volume to zero in a cancer in which that has never been observed
Contact
Non-Confidential
information
3
ATRN-119 Anti-Tumor Highlights
Oral formulation
Higher prescribing rates
High potency &
specificity
Reduced clinical risk
Biomarkers
 6 weeks, then life-long maintenance
 Superior pharmacoeconomics
 Reimbursable under existing codes




Highly effective single agent
Combination with other therapies
Effective in a wide spectrum of cancers
Potential low side effects
 Oncogenic stress (Ras, Myc)
 Alternative lengthening of telomeres (ALT)
 Defects in Homologous Recombination (HR)
pathway (ATM, BRCA1, or BRCA2 deficiency)
Non-Confidential
4
Atrin’s Team, Board Members and Advisors
Oren Gilad, Ph.D – Co-Founder and CEO
Plus
Stellar
Board
 Serial entrepreneur
 Founded and sold two companies
 Named 2015 EY Entrepreneur Of The Year Greater Philadelphia Finalist
Bernard Rudnick – CFO & Strategic Advisor
 Experienced Biotech C-Level executive, Keiretsu Member
 Facilitated exits and transactions valued over $7 billion
Rifat Pamukcu, M.D. – Chief Medical Advisor
 President & CEO of Midway Pharmaceutical
 President & CEO of RxMP Therapeutics
 Founder, Director and Chief Science Officer of Cell Pathways (NASDAQ:CLPA,
acquired by OSI Pharmaceuticals)
Hank Breslin – Head of Chemistry
 Inventor of recently approved IBS-D drug Viberzi (Eluxadoline)
 Former chemist Janssen, J&J and Cephalon
Non-Confidential
5
Company Overview and Value Proposition
Platform Technology
Licensed from the U of Pennsylvania – ROYALTY FREE
ATR Kinase is a
Validated Target
Clear genetic and biochemical rational for developing drugs
that inhibit the ATR kinase
Advanced Lead
Program
ATRN-119 is a potent ATR kinase inhibitor less than 18
months from first in human trials
Multiple Shots
On Goal
Portfolio of additional oncology small molecule drug
candidates encompassing multiple mechanisms of action
Personalized
Medicine Approach
Biomarker identifies patients with the highest probability of
responding to ATRN-119
Strong Team
Management team and advisory board have deep corporate
and drug development and investment expertise
Leaders of the field
First to validate ATR as a target
Non-Confidential
6
Seeking Strategic Partner
Oren Gilad
President and CEO
[email protected]
215-589-6356
Bernard Rudnick
Chief Financial Officer
[email protected]
302-981-9001